What is new in Polish Society of Hypertension Guidelines of the management of arterial hypertension? Review article
Article Sidebar
Published:
Mar 31, 2012
Keywords:
hypertension, guidelines, β-blockers, target blood pressure
Main Article Content
Abstract
Last year, the Polish Hypertension Society published new guidelines on the management of patients with high blood pressure, updating its previous 2008 guidelines. The new guidelines include some major changes regarding such issues as threshold and target blood pressure values for drug therapy, and preference of some antihypertensive drugs over the other. The update is mainly based on new data from clinical studies reported in the recent years, and the latest European Society of Hypertension statement published in 2009. To help practicing physicians become acquainted with these new approaches to some issues in the management of hypertension, this paper provides a critical summary of the changes introduced in the current guidelines compared to the previous position of the Society.
Article Details
How to Cite
Jędrusik , P., & Lewandowski , J. (2012). What is new in Polish Society of Hypertension Guidelines of the management of arterial hypertension?. Medycyna Faktow (J EBM), 5(1(14), 52-61. Retrieved from https://www.journalsmededu.pl/index.php/jebm/article/view/2493
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Nadciśnienie Tętnicze 2011; 15: 55-82.
2. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Kolegium Lekarzy Rodzinnych w Polsce. Zasady postępowania w nadciśnieniu tętniczym. Nadciśnienie Tętnicze 2008; 12(Suplement C): C1-C30.
3. Zanchetti A.: Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J. Hypertens. 2009; 27: 1509-1520.
4. Zanchetti A., Grassi G., Mancia G.: When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J. Hypertens. 2009; 27: 923-934.
5. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27: 2121-2158.
6. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension. J. Hypertens. 2007; 25: 1105-1187.
7. Parati G., Stergiou G.S., Asmar R. et al.: European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J. Hypertens. 2008; 26: 1505-1530.
8. Ernst M.E., Carter B.L., Goerdt C.J. et al.: Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47: 352-358.
9. Zillich A.J., Garg J., Basu S. et al.: Thiazide diuretics, potassium, and the development of diabetes. Hypertension 2006; 48: 219-224.
10. Shafi T., Appel L.J., Miller E.R. et al.: Changes in Serum Potassium Mediate Thiazide-Induced Diabetes. Hypertension 2008; 52: 1022-1029.
11. Bakris G.L., Fonseca V., Katholi R.E. et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA 2004; 292: 2227-2236.
12. Brixius K., Middeke M., Lichtenthial A. et al.: Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED STUDY): Benefit of nebivolol versus metoprolol in hypertensive men. Clin. Exp. Pharmacol. Physiol. 2007; 34: 327-31.
13. Fogari R., Zoppi A., Tettamanti F. et al.: Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J. Cardiovasc. Pharmacol. 1990; 16(suppl. 5): S76-80.
14. Law M.R., Morris J.K., Wald N.J.: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
15. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J. Hypertens. 2011; 29: 623-635.
16. Rosendorff C., Black H.R., Cannon C.P. et al.: Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761-2788.
17. Podymow T., August P.: Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008; 51: 960-969.
2. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Kolegium Lekarzy Rodzinnych w Polsce. Zasady postępowania w nadciśnieniu tętniczym. Nadciśnienie Tętnicze 2008; 12(Suplement C): C1-C30.
3. Zanchetti A.: Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J. Hypertens. 2009; 27: 1509-1520.
4. Zanchetti A., Grassi G., Mancia G.: When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J. Hypertens. 2009; 27: 923-934.
5. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27: 2121-2158.
6. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension. J. Hypertens. 2007; 25: 1105-1187.
7. Parati G., Stergiou G.S., Asmar R. et al.: European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J. Hypertens. 2008; 26: 1505-1530.
8. Ernst M.E., Carter B.L., Goerdt C.J. et al.: Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47: 352-358.
9. Zillich A.J., Garg J., Basu S. et al.: Thiazide diuretics, potassium, and the development of diabetes. Hypertension 2006; 48: 219-224.
10. Shafi T., Appel L.J., Miller E.R. et al.: Changes in Serum Potassium Mediate Thiazide-Induced Diabetes. Hypertension 2008; 52: 1022-1029.
11. Bakris G.L., Fonseca V., Katholi R.E. et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA 2004; 292: 2227-2236.
12. Brixius K., Middeke M., Lichtenthial A. et al.: Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED STUDY): Benefit of nebivolol versus metoprolol in hypertensive men. Clin. Exp. Pharmacol. Physiol. 2007; 34: 327-31.
13. Fogari R., Zoppi A., Tettamanti F. et al.: Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J. Cardiovasc. Pharmacol. 1990; 16(suppl. 5): S76-80.
14. Law M.R., Morris J.K., Wald N.J.: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
15. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J. Hypertens. 2011; 29: 623-635.
16. Rosendorff C., Black H.R., Cannon C.P. et al.: Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761-2788.
17. Podymow T., August P.: Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008; 51: 960-969.